Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
Abstract Background Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. Hypothesis/Objectives Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated wit...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | Journal of Veterinary Internal Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1111/jvim.16178 |
id |
doaj-8ff011e4659c49f58812321a4c63cd80 |
---|---|
record_format |
Article |
spelling |
doaj-8ff011e4659c49f58812321a4c63cd802021-09-28T15:49:30ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762021-09-013552131213910.1111/jvim.16178Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogsMichelle Miller0Jully Pires1Katti Crakes2Rachel Greathouse3Nina Quach4Chen Gilor5Department of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USAAbstract Background Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. Hypothesis/Objectives Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated with less day‐to‐day glucose variability compared to porcine lente (PL) in diabetic dogs. Animals Seven intact male purpose‐bred beagles with toxin‐induced diabetes. Methods In this repeated measured study, PL, IGla300 and IDeg were compared in 2 phases: once‐daily (q24h) and twice‐daily (q12h) administration. Interstitial glucose concentrations (IG) were measured continuously throughout the study. For each formulation, maximal q24h dose was determined using the same algorithm (while avoiding hypoglycemia) and then maintained for 72 hours. In phase 2, 70% of the maximal q24h dose was administered q12h and maintained for 5 days regardless of hypoglycemia. Coefficient of variation (CV) and glycemic variability percentage (GVP) were calculated to determine day‐to‐day and intraday variability, respectively. Results There was no difference in day‐to‐day variability between PL, IGla300, and IDeg in the q24h phase. In the q12h phase, day‐to‐day variability was higher (P = .01) for PL (CV = 42.6 ± 6.8%) compared to IGla300 and IDeg (CV = 30.1 ± 7.7%, 25.2 ± 7.0%, respectively). The GVP of PL was lower (P = .02) compared to IGla300. There was no difference between PL, IGla300 and IDeg in %time IG < 70 mg/dL. Conclusions and Clinical Importance Insulin degludec and IGla300 administered q12h were associated with lower day‐to‐day variability, which might be advantageous in minimizing monitoring requirements without increasing the risk of hypoglycemia.https://doi.org/10.1111/jvim.16178basal insulindiabetes mellitusglycemic variabilityhypoglycemia |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michelle Miller Jully Pires Katti Crakes Rachel Greathouse Nina Quach Chen Gilor |
spellingShingle |
Michelle Miller Jully Pires Katti Crakes Rachel Greathouse Nina Quach Chen Gilor Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs Journal of Veterinary Internal Medicine basal insulin diabetes mellitus glycemic variability hypoglycemia |
author_facet |
Michelle Miller Jully Pires Katti Crakes Rachel Greathouse Nina Quach Chen Gilor |
author_sort |
Michelle Miller |
title |
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs |
title_short |
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs |
title_full |
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs |
title_fullStr |
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs |
title_full_unstemmed |
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs |
title_sort |
day‐to‐day variability of porcine lente, insulin glargine 300 u/ml and insulin degludec in diabetic dogs |
publisher |
Wiley |
series |
Journal of Veterinary Internal Medicine |
issn |
0891-6640 1939-1676 |
publishDate |
2021-09-01 |
description |
Abstract Background Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. Hypothesis/Objectives Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated with less day‐to‐day glucose variability compared to porcine lente (PL) in diabetic dogs. Animals Seven intact male purpose‐bred beagles with toxin‐induced diabetes. Methods In this repeated measured study, PL, IGla300 and IDeg were compared in 2 phases: once‐daily (q24h) and twice‐daily (q12h) administration. Interstitial glucose concentrations (IG) were measured continuously throughout the study. For each formulation, maximal q24h dose was determined using the same algorithm (while avoiding hypoglycemia) and then maintained for 72 hours. In phase 2, 70% of the maximal q24h dose was administered q12h and maintained for 5 days regardless of hypoglycemia. Coefficient of variation (CV) and glycemic variability percentage (GVP) were calculated to determine day‐to‐day and intraday variability, respectively. Results There was no difference in day‐to‐day variability between PL, IGla300, and IDeg in the q24h phase. In the q12h phase, day‐to‐day variability was higher (P = .01) for PL (CV = 42.6 ± 6.8%) compared to IGla300 and IDeg (CV = 30.1 ± 7.7%, 25.2 ± 7.0%, respectively). The GVP of PL was lower (P = .02) compared to IGla300. There was no difference between PL, IGla300 and IDeg in %time IG < 70 mg/dL. Conclusions and Clinical Importance Insulin degludec and IGla300 administered q12h were associated with lower day‐to‐day variability, which might be advantageous in minimizing monitoring requirements without increasing the risk of hypoglycemia. |
topic |
basal insulin diabetes mellitus glycemic variability hypoglycemia |
url |
https://doi.org/10.1111/jvim.16178 |
work_keys_str_mv |
AT michellemiller daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs AT jullypires daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs AT katticrakes daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs AT rachelgreathouse daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs AT ninaquach daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs AT chengilor daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs |
_version_ |
1716865499435892736 |